Palatin Technologies Inc - Company Profile
Powered by 
All the sales intelligence you need on Palatin Technologies Inc in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Palatin Technologies Inc fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Palatin Technologies Inc.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Palatin Technologies Inc (Palatin) is a biopharmaceutical company. Palatin focuses on developing innovative therapeutics targeting the melanocortin receptor (MCR) system. The company's main activities involve researching and designing receptor-specific therapies, including agonists and antagonists, to address various physiological functions. Palatin's major products include treatments for obesity, male sexual dysfunction, and ocular diseases. The company has licensed a product candidate for dry eye disease to a third party and melanocortin receptor compounds for retinal diseases to Boehringer Ingelheim. Palatin's products are used in medical applications across industries such as healthcare and pharmaceuticals, targeting conditions like inflammatory and autoimmune diseases. It is also conducting a Phase 2 study for PL8177, targeting inflammatory bowel diseases, while also progressing with research for diabetic nephropathy and diabetic retinopathy. Palatin is headquartered in Cranbury, New Jersey, the US.
Headquarters
United States of America
Address
301 Carnegie Center Drive, Suite 304, Princeton, New Jersey, 08540
Website
www.palatin.com
Telephone
1 609 4952200
No of Employees
25
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
PTN (NASD)
Revenue (2025)
$13.2M
-100%
(2025 vs 2024)
EPS
XYZ
Net Income (2025)
XYZ
51.6%
(2025 vs 2024)
Market Cap*
$13.2M
Net Profit Margin (2025)
XYZ
87.2%
(2025 vs 2024)
* As of and is in US$
Palatin Technologies Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| - | :- |
| Vyleesi (bremelanotide) - Hypoactive Sexual Desire Disorder | Vyleesi |
| Pipeline: | Palatin |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2025 | Regulatory Approval | In March, the company announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation to PL7737, an oral treatment that activates the melanocortin-4 receptor, for leptin receptor (LEPR) deficiency, including obesity caused by this condition. |
| 2024 | Regulatory Approval | In May, the company received clearance from the US FDA for the IND application to co-administer Bremelanotide with Tirzepatide (GLP-1) for treating obesity. |
| 2023 | Asset Disposal | In December, the company sold Vyleesi to Cosette Pharmaceuticals. |
Competitor Comparison
| Key Parameters | Palatin Technologies Inc | Ardelyx Inc | Rhythm Pharmaceuticals Inc | Eton Pharmaceuticals Inc | Verastem Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Princeton | Waltham | Boston | Deer Park | Needham |
| State/Province | New Jersey | Massachusetts | Massachusetts | Illinois | Massachusetts |
| No. of Employees | 25 | 489 | 414 | 44 | 102 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| John K.A. Prendergast, PhD | Chairman | Executive Board | 2000 | 72 |
| Carl Spana, PhD | Chief Executive Officer; Director; President | Executive Board | 2000 | 63 |
| Stephen T. Wills | Chief Financial Officer; Chief Operating Officer; Secretary; Treasurer | Senior Management | 2011 | 69 |
| Stephen A. Slusher | Assistant Secretary; Chief Legal Officer | Senior Management | 2006 | - |
| James E. Hattersley | Senior Vice President - Business Development | Senior Management | 2021 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer